DU145 (DU-145) and PC3 human prostate cancer cell lines are the "classical" cell lines of prostatic cancer. DU145 cells have moderate metastatic potential compared to PC3 cells which have high metastatic potential.
The DU145 cell line was derived from a central nervous system metastasis, of primary prostate adenocarcinoma origin, removed during a parieto-occipital craniotomy. DU145 are not hormone-sensitive and do not express prostate-specific antigen (PSA).
It has been demonstrated that administration of NFkappaB ligand RANKL promoted DU145 cell invasion in bone, resulting in osteolytic lesions. DU145 cells also produce soluble factors that activate pre-osteoblast precursors and increase RANKL expression, thus facilitating prostate cancer metastasis in bone.
- Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D (April 2006). "DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation". FEBS Lett. 580 (9): 2294–300. doi:10.1016/j.febslet.2006.03.041. PMID 16580667.
- Pulukuri SM, Gondi CS, Lakka SS, et al. (October 2005). "RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo". J. Biol. Chem. 280 (43): 36529–40. doi:10.1074/jbc.M503111200. PMC . PMID 16127174.
- Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (March 1978). "Isolation of a human prostate carcinoma cell line (DU 145)". Int. J. Cancer. 21 (3): 274–81. doi:10.1002/ijc.2910210305. PMID 631930.
- Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F (December 2007). "DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.". Bone. 40 (4): 981–90. doi:10.1016/j.bone.2006.11.006. PMID 17196895.
|This oncology article is a stub. You can help Wikipedia by expanding it.|